Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results
Date:11/5/2010

THE WOODLANDS, Texas, Nov. 5, 2010 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today updated the progress of its drug development programs and reported financial results for the three and nine months ended September 30, 2010.  

"Having established proof-of-concept for two new mechanisms of action in irritable bowel syndrome and diabetes, we are now preparing our drug candidates for the next phase of development, with a focus on formulation and dose selection in order to optimize the ultimate commercial product opportunity for these programs," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon.  "Over the coming months, we are also looking forward to two more proof-of-concept results in rheumatoid arthritis and carcinoid syndrome."

Key Progress in Clinical Pipeline

  • Diabetes:  Lexicon continues to progress its dual sodium-glucose cotransporter 1 (SGLT1) and SGLT2 inhibitor, LX4211, in patients with type 2 diabetes.  In preparation for a 12-week Phase 2b study that is anticipated to initiate around mid-year 2011, a 13-week toxicology study was completed, a prototype tablet has been formulated, and a pharmacokinetic/pharmacodynamic study in humans has been initiated to evaluate the bioequivalence of the solid oral formulation compared to the liquid formulation that was used in the previous studies and to further evaluate various measures of glucose control and GLP-1 signaling.
  • Irritable Bowel Syndrome:  Reformulation
    '/>"/>

  • SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Lexicon to Present at Stifel Nicolaus Healthcare Conference
    2. Lexicon to Present at Morgan Stanley Global Healthcare Conference
    3. Lexicon to Present at Two Major Healthcare Investor Conferences
    4. Lexicon Announces Pricing of Common Stock in Public Offering
    5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
    6. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
    7. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
    8. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
    9. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
    10. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
    11. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... DIEGO, July 30, 2015   Senomyx , Inc. ... taste science technologies to discover, develop, and commercialize novel ... industries, today reported financial results for the second quarter ... of 2015, we remain on track to achieve our ... Chief Executive Officer of the Company. "Since our last ...
    (Date:7/30/2015)... WARRINGTON, Pa. , July 30, 2015 /PRNewswire/ ... announced that it has received the second $1.0M ... Business Innovation Research (SBIR) grant valued at up ... the company,s aerosolized KL4 surfactant as a potential ... lung injury.  Discovery Labs was awarded an initial ...
    (Date:7/29/2015)... July 30, 2015 Sanofi, ... publie ses résultats pour le premier semestre 2015. ... les résultats. Visionner l,interview vidéo et ... Au sommaire de l,interview :  ... Moteurs de croissance - Diabète ...
    (Date:7/29/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) today announced ... Officer has resigned.  The Company has hired Andrew ... in December 2014, as full time interim CFO and ... Andy Ashworth began his employment today, ... transition.  Andy was the Company,s CFO from September 2011 ...
    Breaking Biology Technology:SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
    ... MOUNTAIN VIEW, Calif., May 12 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... quarter ended March 31, 2008 and provided an update ... loss for the 2008,first fiscal quarter, as reported in ... (GAAP), was $14.6 million, compared,to a net loss of ...
    ... IDIX ) announced today that Idenix management,will present ... Annual Global,Healthcare Conference on Tuesday, May 20, 2008 at ... Monte Carlo, Monaco., The live and archived webcast ... Events" in the Idenix Investor Center at, http://www.idenix.com . ...
    ... N.J., May 12 Synvista Therapeutics,Inc. (Amex: SYI ) ... Officer of Synvista will present at the upcoming Rodman,& Renshaw ... 12:10 p.m. CEST (6:10 a.m. EDT). The event will be ... Hotel in Monte Carlo., Dr. Berkowitz will discuss the ...
    Cached Biology Technology:Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 2Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 3Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 4Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 5Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 6Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 7Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 8Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 9Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 10Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference 2Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference 3
    (Date:7/30/2015)... VIEW, Calif. , July 30, 2015 /PRNewswire/ ... and services for gene function analysis and biomarker ... Guide RNA (sgRNA) Knockout Library targeting all human ... specifically and permanently "knock out" a gene,s function. ... provides a high throughput screening tool so that ...
    (Date:7/27/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that Huawei has selected the Synaptics ® ... stylish smartwatch. Huawei chose the state-of-the-art ClearPad capacitive ... and highly responsive human interface qualities such as ... required a classic round watch face and Synaptics ...
    (Date:7/27/2015)... LOS ANGELES , July 27, 2015 /PRNewswire/ ... providing evidence- and experience-based clinical improvement solutions, today ... coordination solution is now available on Android smartphones ... at inpatient and post-care organizations can use ZynxCarebook ... the same patient,s condition, streamline care transitions to ...
    Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
    ... 2009 A canine chromosome 7 locus that confers ... identified through a collaboration between the Behavior Service at ... Medical Genetics at the University of Massachusetts Medical School ... Technology. The findings are published in the January 2010 ...
    ... lll. Researchers report that Helicobacter pylori , ... environment of the human stomach, directly activates an enzyme ... types of cancer, including gastric cancer. Chronic infection ... factor for several forms of gastric cancer, but researchers ...
    ... scientific conference has provided new evidence for the ... of spectacular marine life, including deadly jellyfish, basking ... ,South West Marine Ecosystems, meeting, held in Plymouth ... the scientific, conservation, fishing and eco-tourism sectors. The ...
    Cached Biology News:Canine compulsive disorder gene identified in dogs 2Canine compulsive disorder gene identified in dogs 3Team finds link between stomach-cancer bug and cancer-promoting factor 2Team finds link between stomach-cancer bug and cancer-promoting factor 3Conference highlights impact of unsettled summer weather on UK marine life 2
    Recombinant Mouse TGF-beta RII/(human) Fc Chimera, CF...
    Recombinant Mouse Noggin...
    ... Deacetylase (HDAC) Antibody Sampler Kit Kit ... Catalog #2062, 40 ul Histone Deacetylase 3 ... Deacetylase 4 (HDAC4) Antibody, Catalog #2072, 40 ... #2082, 40 ul Histone Deacetylase 6 (HDAC6) ...
    An instrument that delivers an accurate and uniform amount of light energy to cells to photoactivate csiRNA products....
    Biology Products: